

2031249PC.ST25.txt  
SEQUENCE LISTING

<110> Karyon Oy Ab  
<120> Tumor targeting agents and uses thereof  
<130> 2031249PC  
<150> FI 20021761  
<151> 2002-10-03  
<160> 7  
<170> PatentIn version 3.2  
<210> 1  
<211> 5  
<212> PRT  
<213> Artificial  
<220>  
<223> synthetic  
  
<220>  
<221> MISC\_FEATURE  
<222> (1)..(5)  
<223> cysteine bridge  
  
<400> 1

Cys Leu Arg Ser Cys  
1 5

<210> 2  
<211> 5  
<212> PRT  
<213> Artificial

<220>  
<223> synthetic

<220>  
<221> MISC\_FEATURE  
<222> (1)..(5)  
<223> cysteine bridge

<400> 2

Cys Ser Arg Leu Cys  
1 5

<210> 3  
<211> 5  
<212> PRT  
<213> Artificial

<220>  
<223> synthetic

<220>  
<221> MISC\_FEATURE  
<222> (1)..(5)  
<223> lactam bridge

<400> 3

Asp Leu Arg Ser Lys  
1 5

<210> 4  
<211> 7  
<212> PRT  
<213> Artificial

<220>  
<223> synthetic

<220>  
<221> MISC\_FEATURE  
<222> (1)..(7)  
<223> lactam bridge

<400> 4

Asp Leu Arg Ser Gly Arg Lys  
1 5

<210> 5  
<211> 7  
<212> PRT  
<213> Artificial

<220>  
<223> synthetic

<220>  
<221> MISC\_FEATURE  
<222> (1)..(7)  
<223> lactam bridge

<400> 5

Asp Arg Gly Leu Arg Ser Lys  
1 5

<210> 6  
<211> 5  
<212> PRT  
<213> Artificial

<220>  
<223> synthetic

<220>  
<221> MISC\_FEATURE  
<222> (1)..(5)  
<223> amide bond

<220>  
<221> MISC\_FEATURE  
<222> (1)..(1)  
<223> Ornithine

<400> 6

Xaa Leu Arg Ser Glu  
1 5

<210> 7  
<211> 5  
<212> PRT  
<213> Artificial

<220>  
<223> synthetic

<220>  
<221> MISC\_FEATURE  
<222> (1)..(5)  
<223> lactam bridge

<400> 7

Lys Leu Arg Ser Asp  
1 5